Earnings ·
Vanda reports Q3 revenue of $69.8M, up 24% YoY; updates full-year guidance above $240M
VNDAVanda Pharmaceuticals Inc.
Vanda Pharmaceuticals reported third-quarter 2026 total net product sales of $69.8 million, a 24% increase from the prior year period and a 38% rise compared to Q2 2026. Operating expenses decreased by 18% sequentially to $93.3 million as key Phase III and launch-preparation activities concluded. The company announced positive results from the Phase III study of NEREUS for preventing GLP-1-induced vomiting, with plans to submit a supplemental New Drug Application. Additionally, Vanda updated its full-year 2026 financial guidance, expecting total revenue to exceed $240 million. The firm operates in the biopharmaceutical industry, developing and commercializing innovative therapies for high unmet medical needs.